4 December 2018

Pieter Roelofs, PhD candidate at the Radiotherapy & OncoImmunology laboratory, Dept. of Radiation Oncology, was awarded a 3500 EUR travel grant from the René Vogels Stichting.

He received the award in order to perform a work visit to prof. Reuben Harris’ lab at the University of Minnesota, Minneapolis, MN, USA. Pieter’s work is focused on the role of the DNA cytosine deaminase APOBEC3B in the development of therapy resistance in breast cancer. During his 14-months stay in Minneapolis as part of his KWF-funded project, he will investigate why this anti-viral enzyme is deregulated in a large proportion of breast tumors, leading to increased mutations and subsequent therapy resistance.

Pieter Roelofs is member of theme Women´s cancers.

Related news items


Nontuberculous mycobacteria and fungal co-infections Bonnie and Clyde?

18 April 2019

In The European respiratory journal Jakko van Ingen and Sanne Zweijpfenning showed that 40% of patients diagnosed with nontuberculous mycobacterial pulmonary disease also meet diagnostic criteria for chronic pulmonary aspergillosis.

read more

ESCMID award for groundbreaking studies on NTM disease

18 April 2019

Jakko van Ingen received the ESCMID Young Investigator Award for his groundbreaking work on nontuberculous mycobacterial disease.

read more

Honorary Membership Japanese Radiological Society

18 April 2019

Jelle Barentsz became in Yokohama during the annual meeting of the Japanese Radiological Society Honary Member.

read more

EU funded project BIOMAP led by Ellen van den Bogaard

12 April 2019

Ellen van den Bogaard, theme Inflammatory diseases, leads the research on the experimental validation and functional analysis of identified biomarkers by using advanced organotypic skin models and receives a grant of €258,000.

read more

Academic workshop AMPHI part of vaccination alliance

11 April 2019

Last month State Secretary Paul Blokhuis (VWS) gave the go-ahead for the national vaccination alliance.

read more

Dosing anticancer drugs in patients with renal or hepatic impairment

11 April 2019

Renal or hepatic impairment is a common comorbidity for patients with cancer either because of the disease itself, toxicity of previous anticancer treatments, or because of other factors affecting organ function, such as increased age.

read more